What is APLM's earnings growth forecast for 2026-2026?
(NASDAQ: APLM) Apollomics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Apollomics's earnings in 2026 is -$31,188,000.
In 2026, APLM is forecast to generate -$1,373,006 in earnings, with the lowest earnings forecast at -$1,319,163 and the highest earnings forecast at -$1,413,389.
What is APLM's revenue growth forecast for 2026-2026?
(NASDAQ: APLM) Apollomics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Apollomics's revenue in 2026 is $8,500,000.
In 2026, APLM is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.
What is APLM's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: APLM) forecast ROA is -12.35%, which is lower than the forecast US Biotechnology industry average of 16.67%.
What is APLM's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: APLM) Apollomics's current Earnings Per Share (EPS) is -$26.17. In 2026, APLM's EPS is forecast to hit -$1.24 (min: -$1.20, max: -$1.28).
What is APLM's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: APLM) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.